Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Silvia Bader‐Weder"'
Autor:
Jennifer M. Kwon, Kapil Arya, Nancy Kuntz, Han C. Phan, Cory Sieburg, Kathryn J. Swoboda, Aravindhan Veerapandiyan, Beverly Assman, Silvia Bader‐Weder, Travis L. Dickendesher, Jennifer Hansen, Helen Lin, Ying Yan, Vamshi K. Rao, US Expanded Access Program Working Group
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 9, Iss 6, Pp 810-818 (2022)
Abstract Objective The US risdiplam expanded access program (EAP; NCT04256265) was opened to provide individuals with Type 1 or 2 spinal muscular atrophy (SMA) who had no satisfactory treatment options access to risdiplam prior to commercial availabi
Externí odkaz:
https://doaj.org/article/348024081e884c6d917cf3217cdb8543
Autor:
Ilona, Große-Michaelis, Scott, Proestel, Radhika M, Rao, Brian S, Dillman, Silvia, Bader-Weder, Lynn, Macdonald, William, Gregory
Publikováno v:
Therapeutic Innovation & Regulatory Science. 57:1-6
The granularity and structure of the International Council for Harmonisation’s (ICH) Medical Dictionary for Regulatory Activities (MedDRA) are useful for precise coding of adverse events (AEs) for data analysis. In product labeling for healthcare p
Autor:
Eugenio, Mercuri, Giovanni, Baranello, Odile, Boespflug-Tanguy, Liesbeth, De Waele, Nathalie, Goemans, Janbernd, Kirschner, Riccardo, Masson, Elena S, Mazzone, Astrid, Pechmann, Maria Carmela, Pera, Carole, Vuillerot, Silvia, Bader-Weder, Marianne, Gerber, Ksenija, Gorni, Janine, Hoffart, Heidemarie, Kletzl, Carmen, Martin, Tammy, McIver, Renata S, Scalco, Wai Yin, Yeung, Laurent, Servais
Publikováno v:
European journal of neurologyREFERENCES.
BACKGROUND AND PURPOSE: Spinal muscular atrophy (SMA) is caused by reduced levels of survival of motor neuron (SMN) protein due to deletions and/or mutations in the SMN1 gene. Risdiplam is an orally administered molecule that modifies SMN2 pre-mRNA s
Autor:
Silvia Bader-Weder, Barbara Donner, Michael M. Peng, James R. Smith, Roman Schwarz, Vis Niranjan
Publikováno v:
Pharmacoepidemiology and Drug Safety. 20:532-543
Purpose This study evaluated the safety of oseltamivir during the 2009 influenza pandemic. Methods Case reports were obtained from the Roche safety database. The incidence of adverse events (AEs) during the pandemic (1 May 2009 to 31 December 2009) w
Autor:
Barbara, Donner, Silvia, Bader-Weder, Roman, Schwarz, Michael M, Peng, James Robert, Smith, Viswanathan, Niranjan
Publikováno v:
Pharmacoepidemiology and drug safety. 20(5)
This study evaluated the safety of oseltamivir during the 2009 influenza pandemic.Case reports were obtained from the Roche safety database. The incidence of adverse events (AEs) during the pandemic (1 May 2009 to 31 December 2009) was compared with
Autor:
Tosca Kinchelow, Denise Guimaraes, Peter J. Piliero, Miklos Salgo, David A. Cooper, Fiona Hughes, Calvin Cohen, Emily Labriola-Tompkins, Hans-Jiirgen Stellbrink, Silvia Bader-Weder, Lynn Smiley, Laurence Bourdeau, Daniel R. Kuritzkes, Benoit Trottier, Anne Bertasso, Julio S. G. Montaner, Joep M. A. Lange, Adriano Lazzarin, Sharon Walmsley, Christine Katlama, Jacques Reynes, Mary O'Hearn, Jacob Lalezari, Keith Henry, Jean-François Delfraissy, Belinda Atkins, Keikanus Arasteh, Bonaventura Clotet, Anna Shikhman, Mark T. Nelson, Jain Chung, Ralph DeMasi, Claude Drobnes, Christopher Natale, Joseph J. Eron
Publikováno v:
Journal of acquired immune deficiency syndromes (1999), 40(4), 413-421. Lippincott Williams and Wilkins
Background: Antiretroviral tolerability is a critical factor contributing to treatment outcome. The T-20 Versus Optimized Background Regimen Only (TORO) studies assessed the safety and efficacy of enfuvirtide in treatment-experienced HIV-1-infected p